Literature DB >> 15629461

An RNA aptamer that binds to the beta-catenin interaction domain of TCF-1 protein.

Su Kyung Lee1, Min Woo Park, Eun Gyeong Yang, Jaehoon Yu, Sunjoo Jeong.   

Abstract

The architectural transcription factor TCF-1 interacts directly with beta-catenin and activates transcription of various target genes that are important for early development and carcinogenesis. We selected an RNA aptamer that specifically bound to the beta-catenin-interacting N-terminal motif of TCF-1. Structural analysis revealed that it formed a stem-loop structure that was responsible for binding TCF-1 and contained a pair of internal loops. The RNA aptamer interfered with the binding of TCF-1 to beta-catenin and also inhibited the formation of TCF-1/beta-catenin complexes. Disruption of TCF-1/beta-catenin complexes could alter the transcriptional activity of TCF-1. Taken together our observations show that a rationally designed RNA aptamer can disrupt protein-protein interactions required for the formation of an active transcription complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629461     DOI: 10.1016/j.bbrc.2004.12.011

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

2.  A mathematical analysis of SELEX.

Authors:  Howard A Levine; Marit Nilsen-Hamilton
Journal:  Comput Biol Chem       Date:  2007-01-10       Impact factor: 2.877

Review 3.  Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.

Authors:  Somayeh Vandghanooni; Morteza Eskandani; Jaleh Barar; Yadollah Omidi
Journal:  J Mol Med (Berl)       Date:  2018-07-28       Impact factor: 4.599

Review 4.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

5.  Local neutral networks help maintain inaccurately replicating ribozymes.

Authors:  András Szilágyi; Ádám Kun; Eörs Szathmáry
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 6.  Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.

Authors:  Andrea Conidi; Veronique van den Berghe; Danny Huylebroeck
Journal:  Int J Mol Sci       Date:  2013-03-26       Impact factor: 5.923

Review 7.  Nucleic acid aptamers: research tools in disease diagnostics and therapeutics.

Authors:  Baby Santosh; Pramod K Yadava
Journal:  Biomed Res Int       Date:  2014-06-22       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.